Nanomedicine and experimental tuberculosis: facts, flaws, and future

Abstract Nanoparticle-based drug delivery systems form the crux of nanomedicine and are suitable for targeting chronic diseases such as tuberculosis. Extensive experimental data supports the possibility of intermittent chemotherapy with key first-line as well as second-line antituberculosis drugs by employing synthetic or natural carriers, chiefly polymers. Besides sustained release of drugs in plasma and organs, other potential advantages of the system include the possibility of selecting various routes of chemotherapy; reduction in drug dosage, adverse effects, and drug interactions; and targeting drug-resistant and latent bacteria. On the other hand, the choice of carrier, large-scale production, stability, and toxicity of the formulation are some of the major issues that merit immediate attention and resolution. Nevertheless, keeping in view the hurdles in new antituberculosis drug development, nanomedicine has provided a sound platform and a ray of hope for an onslaught against tuberculosis. From the Clinical Editor Tuberculosis remains a major public health concern worldwide. In this paper, the role and significance of nanoparticle-based drug delivery systems are discussed for targeting tuberculosis, including strains that are drug resistant with conventional methods.